ZURA
NASDAQZura Bio Limited
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$3.67-0.22 (-5.65%)
01:30 PM07:45 PM
News · 26 weeks540%
2025-12-072026-05-31
Mix2390d
- SEC Filings9(39%)
- Other6(26%)
- Insider5(22%)
- Offering2(9%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by Zura Bio LimitedDEFA14A - Zura Bio Ltd (0001855644) (Filer)
- SECSEC Form 8-K filed by Zura Bio Limited8-K - Zura Bio Ltd (0001855644) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zura Bio LimitedSCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zura Bio LimitedSCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)
- PRZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on May 13, 2026, the Company granted an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares (the "Option") to Muzammil Mustufa, the Company's new Chief Business Officer. The award was approved by the Compensation Committee of the Company's Board of Directors and granted outside the Company's 2023 Equity Incentive Plan (the "Plan"), with a grant date of May 13, 2026, as an induceme
- PRZura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business OfficerZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts. Mr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology experience to Zura, with extensive experience in immunology, rare disease, and other therapeutic areas. Most recently, he served as Vice President of Corporate Strategy at Amic
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zura Bio LimitedSCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)
- SECZura Bio Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- SECSEC Form 10-Q filed by Zura Bio Limited10-Q - Zura Bio Ltd (0001855644) (Filer)
- PRZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesContinuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines Strengthened leadership team with key executive and Board appointments Completed an underwritten public offering in February 2026, resulting in gross proceeds of approximately $144 million to support advancement of its pipeline Cash and cash equivalents of $225.6 million as of March 31, 2026, which is expected to fund planned operations through at least the end of 2028 Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and d
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Zura Bio LimitedSCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)
- PRZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the "Options") to eight newly hired employees. These awards were approved by the Compensation Committee of the Company's Board of Directors and granted outside the Company's 2023 Equity Incentive Plan (the "Plan"), with a grant date of April 30, 2026, as inducements material to the new emplo
- SECSEC Form DEF 14A filed by Zura Bio LimitedDEF 14A - Zura Bio Ltd (0001855644) (Filer)
- SECZura Bio Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- INSIDERSEC Form 4 filed by Davis Kim4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Nistala Kiran4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Hyllengren Eric J4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Whale Gary4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 4 filed by Kulkarni Sandeep Chidambar4 - Zura Bio Ltd (0001855644) (Issuer)
- SECSEC Form 10-K filed by Zura Bio Limited10-K - Zura Bio Ltd (0001855644) (Filer)
- SECZura Bio Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- PRZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesAdvancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 Cash and cash equivalents of $109.4 million as of December 31, 2025 Completed an underwritten public offering in February 2026 for gross proceeds of approximately $144 million; post‑financing cash and cash equivalents expected to support planned operations through at least the end of 2028 Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical‑stage biotechnology company developing novel and differentiated medi
- SECZura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zura Bio Ltd (0001855644) (Filer)
- INSIDERSEC Form 4 filed by Director Nirula Ajay4 - Zura Bio Ltd (0001855644) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nirula Ajay3 - Zura Bio Ltd (0001855644) (Issuer)
ZURA FAQ
5 questionsWhere does ZURA stock trade?
Zura Bio Limited (ZURA) is listed on NASDAQ.What sector and industry is ZURA in?
Zura Bio Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ZURA?
Zura Bio Limited has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $1500.00 price target on 2026-02-09.What companies are similar to ZURA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ZURA side-by-side with any of them on Quantisnow.How can I track ZURA on Quantisnow?
Quantisnow aggregates Zura Bio Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZURA to receive live email and push alerts on every new disclosure.